HUE032251T2 - Neuroprotekció a demyelinizációs betegségekben - Google Patents
Neuroprotekció a demyelinizációs betegségekben Download PDFInfo
- Publication number
- HUE032251T2 HUE032251T2 HUE08737369A HUE08737369A HUE032251T2 HU E032251 T2 HUE032251 T2 HU E032251T2 HU E08737369 A HUE08737369 A HU E08737369A HU E08737369 A HUE08737369 A HU E08737369A HU E032251 T2 HUE032251 T2 HU E032251T2
- Authority
- HU
- Hungary
- Prior art keywords
- compound
- salt
- subject
- therapeutically effective
- disease
- Prior art date
Links
- 208000016192 Demyelinating disease Diseases 0.000 title abstract description 31
- 230000004112 neuroprotection Effects 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims description 65
- 150000003839 salts Chemical class 0.000 claims description 39
- 230000000750 progressive effect Effects 0.000 claims description 18
- 238000011282 treatment Methods 0.000 claims description 12
- 210000004556 brain Anatomy 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims 2
- 244000025254 Cannabis sativa Species 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- 230000000386 athletic effect Effects 0.000 claims 1
- 239000011230 binding agent Substances 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003380 propellant Substances 0.000 claims 1
- NKHAVTQWNUWKEO-NSCUHMNNSA-N monomethyl fumarate Chemical compound COC(=O)\C=C\C(O)=O NKHAVTQWNUWKEO-NSCUHMNNSA-N 0.000 abstract description 44
- LDCRTTXIJACKKU-ONEGZZNKSA-N dimethyl fumarate Chemical compound COC(=O)\C=C\C(=O)OC LDCRTTXIJACKKU-ONEGZZNKSA-N 0.000 abstract description 42
- 229960004419 dimethyl fumarate Drugs 0.000 abstract description 41
- NKHAVTQWNUWKEO-UHFFFAOYSA-N fumaric acid monomethyl ester Natural products COC(=O)C=CC(O)=O NKHAVTQWNUWKEO-UHFFFAOYSA-N 0.000 abstract description 38
- 229940005650 monomethyl fumarate Drugs 0.000 abstract description 38
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 30
- 206010012305 Demyelination Diseases 0.000 abstract description 24
- 230000003376 axonal effect Effects 0.000 abstract description 19
- 208000035475 disorder Diseases 0.000 abstract description 13
- 201000008628 secondary progressive multiple sclerosis Diseases 0.000 abstract description 12
- 208000012902 Nervous system disease Diseases 0.000 abstract description 8
- 208000008795 neuromyelitis optica Diseases 0.000 abstract description 6
- 208000025966 Neurological disease Diseases 0.000 abstract description 5
- 208000007118 chronic progressive multiple sclerosis Diseases 0.000 abstract description 5
- 238000000034 method Methods 0.000 abstract description 5
- 201000006417 multiple sclerosis Diseases 0.000 description 28
- 241000699670 Mus sp. Species 0.000 description 22
- 201000010099 disease Diseases 0.000 description 17
- -1 microtablets Substances 0.000 description 14
- 239000002775 capsule Substances 0.000 description 13
- 230000003902 lesion Effects 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 206010061218 Inflammation Diseases 0.000 description 9
- 229920003091 Methocel™ Polymers 0.000 description 9
- 230000004054 inflammatory process Effects 0.000 description 9
- 210000003169 central nervous system Anatomy 0.000 description 8
- 206010036807 progressive multifocal leukoencephalopathy Diseases 0.000 description 8
- 210000000278 spinal cord Anatomy 0.000 description 8
- 206010061818 Disease progression Diseases 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 6
- 230000005750 disease progression Effects 0.000 description 6
- 230000007170 pathology Effects 0.000 description 6
- CGBYBGVMDAPUIH-ONEGZZNKSA-N (e)-2,3-dimethylbut-2-enedioic acid Chemical compound OC(=O)C(/C)=C(\C)C(O)=O CGBYBGVMDAPUIH-ONEGZZNKSA-N 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 5
- 210000004885 white matter Anatomy 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 208000033068 episodic angioedema with eosinophilia Diseases 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 210000000274 microglia Anatomy 0.000 description 4
- 230000000324 neuroprotective effect Effects 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- 206010063401 primary progressive multiple sclerosis Diseases 0.000 description 4
- 230000002459 sustained effect Effects 0.000 description 4
- 241000701460 JC polyomavirus Species 0.000 description 3
- 102000006386 Myelin Proteins Human genes 0.000 description 3
- 108010083674 Myelin Proteins Proteins 0.000 description 3
- 206010033885 Paraparesis Diseases 0.000 description 3
- 210000003050 axon Anatomy 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 3
- 230000006735 deficit Effects 0.000 description 3
- 230000007850 degeneration Effects 0.000 description 3
- 230000003210 demyelinating effect Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000012669 liquid formulation Substances 0.000 description 3
- 210000005012 myelin Anatomy 0.000 description 3
- 210000000653 nervous system Anatomy 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 230000004770 neurodegeneration Effects 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 210000004248 oligodendroglia Anatomy 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 208000037821 progressive disease Diseases 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- 206010067063 Progressive relapsing multiple sclerosis Diseases 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 208000034189 Sclerosis Diseases 0.000 description 2
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 description 2
- 229920013820 alkyl cellulose Polymers 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000003416 augmentation Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 description 2
- 238000011461 current therapy Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 210000005230 lumbar spinal cord Anatomy 0.000 description 2
- 230000007971 neurological deficit Effects 0.000 description 2
- 230000016273 neuron death Effects 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 208000005622 Gait Ataxia Diseases 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000032087 Hereditary Leber Optic Atrophy Diseases 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- 201000000639 Leber hereditary optic neuropathy Diseases 0.000 description 1
- LUWJPTVQOMUZLW-UHFFFAOYSA-N Luxol fast blue MBS Chemical compound [Cu++].Cc1ccccc1N\C(N)=N\c1ccccc1C.Cc1ccccc1N\C(N)=N\c1ccccc1C.OS(=O)(=O)c1cccc2c3nc(nc4nc([n-]c5[n-]c(nc6nc(n3)c3ccccc63)c3c(cccc53)S(O)(=O)=O)c3ccccc43)c12 LUWJPTVQOMUZLW-UHFFFAOYSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 101001013647 Mus musculus Methionine synthase Proteins 0.000 description 1
- 101100077708 Mus musculus Mog gene Proteins 0.000 description 1
- 208000008457 Neurologic Manifestations Diseases 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- 208000003435 Optic Neuritis Diseases 0.000 description 1
- 206010033892 Paraplegia Diseases 0.000 description 1
- 108010081690 Pertussis Toxin Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241001505332 Polyomavirus sp. Species 0.000 description 1
- 239000012891 Ringer solution Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 208000018254 acute transverse myelitis Diseases 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000007844 axonal damage Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- MPVDXIMFBOLMNW-UHFFFAOYSA-N chembl1615565 Chemical compound OC1=CC=C2C=C(S(O)(=O)=O)C=C(S(O)(=O)=O)C2=C1N=NC1=CC=CC=C1 MPVDXIMFBOLMNW-UHFFFAOYSA-N 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 210000000877 corpus callosum Anatomy 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 206010061811 demyelinating polyneuropathy Diseases 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002888 effect on disease Effects 0.000 description 1
- 230000001712 encephalitogenic effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 239000001761 ethyl methyl cellulose Substances 0.000 description 1
- 235000010944 ethyl methyl cellulose Nutrition 0.000 description 1
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000004884 grey matter Anatomy 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 229920013821 hydroxy alkyl cellulose Polymers 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 208000036546 leukodystrophy Diseases 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000000627 locus coeruleus Anatomy 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000001259 mesencephalon Anatomy 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 210000000337 motor cortex Anatomy 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 230000008035 nerve activity Effects 0.000 description 1
- 230000007830 nerve conduction Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000009251 neurologic dysfunction Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000003961 neuronal insult Effects 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000002516 postimmunization Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000011809 primate model Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000007101 progressive neurodegeneration Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 210000004129 prosencephalon Anatomy 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000008263 repair mechanism Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 210000004092 somatosensory cortex Anatomy 0.000 description 1
- 229910052712 strontium Inorganic materials 0.000 description 1
- 210000003523 substantia nigra Anatomy 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 208000009174 transverse myelitis Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Claims (7)
- igénypontok1. Ιβρ||ί>ί; ;ëgy yegyötei :Éúfet|Au?bátlft ei mon^:^^ÿî|^fMFÎMifiiiiï·· vagy ««Kn*+ egy gy^gv^erészebk-g elfogadható sôjgç fi sÄiii ÉftÉBlffax =pr^Spg:s^iM:s:f#^iajp^^: η,νν kon vertek Kví e^-ber ,3 3 te1 v'zn-u ;\re i; .Az 1, igénypont szedni! felhasználású vegvQlet vagy sé. ahol as alany legalább egy ppní; növekedést mutatott a Kiterjedten Korlátozottság! Skaiáo (£D$S) a vegyidet beadásét megeidző egy év során, ék A2 i- igénypont -szerien felhasználású xífgyifcvap é,0&:m>ém0· ttÉlí lt növekedés volt roegfigyehető a TMezíókban a vegyidét beadását megeldzb egy év során, % A*. í. Igénypont szerinti felhasználásé vegyüfet vagy só, ahol as alany £ö$$ pontszámú iJégpláhlyl.
- 5. Az 1. Igénypont szerinti felhasználású vegyUlet vagy só, ahol az alanynak legalább 10 fepolntenzív TI iéslója van.
- 6. Az II. igénypont szerinti felhaszrfePbd vegyuleí vagy só, ahol az alany primer progresszív sderosk niultipíevben szenved, T, Az 1, igénypont szerint» felhasználású vegyület vagy só, ahoi az alany szekunder 3 Og 3s ' > is < >U.ÍÍ ib\D3' e uc s A 7· ‘«énypont szerinti felhasználású vegyület vagy só, ahol az alany bPSS pontja 5-né! 15bb. 9, legaiáhh egy vágyóiét :dtm8í!l4krmafát -és monöíhétih%s:möráÍ: körűi; válastiva, vagy ezeknek regy gyógysaatüssatikg slfegadhaté sbía:, a Davfcr'saindrôma'-âlâf^y.ôkô^ végastt kezelésiben vsáé-fblhasz oá Sásra ; KL Ai fei:· Igénypontok bármelyike szerinti felhasználású. vegyüfei vagy m·. ekei a végyülétek orálisan adagoljuk tempiässn hatásos dtkisban. Ü, A 10. Igénypont szerinti felhas^áiásü va gy Ó lét vagy só, ahol a terápiásán hatásos dórié naps körülbelül 2ÖÖ mg és körülbelül 90ü mg közeitt van. II;. A ti, igèoyporst sïermtÀfelhassnàlàsb vegyület vagy só, ahol a terápiásán: hatásos dbais Papi kötölfMlül Aiö mg és körülbelül ?2ömsg kbfett van, 13. A 13> Igénypont saeorstl teSbasaoáiású vegyidet vagy só, ahol a terápiásán hatásos dózis napi körülbelül ASÜrng, 14. A11. igénypont seehnii fslbasanáiásü vegyület vagy sé, ahol a ivrápiásun hatásos dbass rsspl körülbelül 320 mg.
- 13. A lifeiA. Igénypontok bármelyike szerinti felbassnálásü vegyidet vagy sé, aboi a terápiásán hatásos döalst 12, 3, 4 vagy bkűlön átló, egyenlő désisbars adjuk be,
- 16, A IS. Igénypont sserinh félhassoálásö vegyület vagy $4 Ahol a dohát 2 thllőp álló, egy en ló d 021 sfean a djok lse.12. A IS, Igénypont szerinti felhasználása vegyidet vagy sö; ahol a dózist .3: külön álló, egyénid dózisban adjuk be. IS As 1~·!Ά Igénypontok bármelyike szerinti íelhassrmlásü vegyulet vagy só, also; a vegyület dlmetlbfonraráí,
- 19. Az fel?. Igénypontok bármelyike szétiutj felhasználású vegyülni vagy: só, ahol a vegyül üt fn pnpm eh I fűm a tat. 2öL Λ»; 1-1¾. y-aoypoatok béíUSélykko sSOSIaé foibasmalásü yagyötpt vagy so, ahol a vogyéfyt bbufák,. táblatígk, rolkrotubloilàl.: pgjletak, mikmp©lte.t«kv kaiVVblak, pailcyptlblgtrlkat tartalmlaé kaéskuiak vagy fQlysdekoklbfbiiJspao van orális adagolásra. 3:¾.. A?. 1 "dg, sgéoypordok bármi: iyika srs-rinb félbáSSOatáSé vagyOlM vagy só, aboi a lalhassoélás agy Vágy ïóbb oiyao líSpSlolá Prills ijovétaléî ioiooll. arnoiy agy alagvmőoo 60-240 mg dkootll·lumpralééi âlé gyégysseréasgt! kémítmaoyt tartalmas. ?:i< A 3:1. Igééyponl Sselml! folbásióalásu vagyûlpt vagy sé; ahol a: folbasioáiás agy vagy tölsó olyaó klgsoülg orális égyérolgt: jllghty Pméiy égy alApVíéoéé HO mg dl moblVumpf árból allé gyégysééléilvtl láságmáéyítérraliéés,
- 23, M X-22:. igébypontók blmmlylkv síénél! feblissbállké yggyüivt vagy sé, ahol a vágyóiétól elbúrodo vagy mabèlyorott hatérrnya-p leadása gyógyrnedorombaa adagokuk.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US88892507P | 2007-02-08 | 2007-02-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE032251T2 true HUE032251T2 (hu) | 2017-09-28 |
Family
ID=39682167
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE08737369A HUE032251T2 (hu) | 2007-02-08 | 2008-02-07 | Neuroprotekció a demyelinizációs betegségekben |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US20100130607A1 (hu) |
| EP (2) | EP2139467B1 (hu) |
| DK (1) | DK2139467T3 (hu) |
| ES (1) | ES2599227T3 (hu) |
| HR (1) | HRP20161233T1 (hu) |
| HU (1) | HUE032251T2 (hu) |
| LT (1) | LT2139467T (hu) |
| PL (1) | PL2139467T3 (hu) |
| PT (1) | PT2139467T (hu) |
| RS (1) | RS55215B1 (hu) |
| SI (1) | SI2139467T1 (hu) |
| WO (1) | WO2008096271A2 (hu) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19853487A1 (de) | 1998-11-19 | 2000-05-25 | Fumapharm Ag Muri | Verwendung von Dialkylfumaraten |
| DK1663197T3 (da) * | 2003-09-09 | 2008-01-07 | Fumapharm Ag | Anvendelse af fumarsyrederivater til behandling af hjerteinsuffiens og astma |
| SI1799196T1 (sl) | 2004-10-08 | 2016-10-28 | Forward Pharma A/S | Farmacevtski sestavki z nadzorovanim sproščanjem, obsegajoči ester fumarne kisline |
| EP2653873B8 (en) | 2007-02-08 | 2022-08-24 | Biogen MA Inc. | Compositions and uses for treating Multiple Sclerosis |
| HUE032251T2 (hu) | 2007-02-08 | 2017-09-28 | Biogen Ma Inc | Neuroprotekció a demyelinizációs betegségekben |
| MX2011001341A (es) | 2008-08-19 | 2011-03-29 | Xenoport Inc | Prodrogas de metil hidrogeno fumarato, sus composiciones farmaceuticas, y metodos de uso. |
| EP2564839B1 (en) | 2009-01-09 | 2016-05-11 | Forward Pharma A/S | Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix |
| EP3318249A1 (en) * | 2009-04-29 | 2018-05-09 | Biogen MA Inc. | Dimethyl fumarate dosage regimens for the treatment of multiple sclerosis |
| DK2533634T3 (en) | 2010-02-12 | 2016-01-25 | Biogen Ma Inc | NEURO PROTECTIVE demyelinating diseases |
| MX2013013781A (es) * | 2011-05-26 | 2014-01-08 | Biogen Idec Inc | Metodos para tratar la esclerosis multiple y preservar y/o aumentar el contenido de mielina. |
| PE20141639A1 (es) | 2011-06-08 | 2014-11-08 | Biogen Idec Inc | Proceso para preparar fumarato de dimetilo de alta pureza y cristalino |
| US9504679B2 (en) | 2011-12-19 | 2016-11-29 | Bjoern Colin Kahrs | Pharmaceutical compositions comprising glitazones and Nrf2 activators |
| US20130158077A1 (en) | 2011-12-19 | 2013-06-20 | Ares Trading S.A. | Pharmaceutical compositions |
| US20130259856A1 (en) * | 2012-03-27 | 2013-10-03 | Teva Pharmaceutical Industries, Ltd. | Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate |
| US9597292B2 (en) | 2012-08-22 | 2017-03-21 | Xenoport, Inc. | Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof |
| EP2887934A1 (en) | 2012-08-22 | 2015-07-01 | XenoPort, Inc. | Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects |
| UA119032C2 (uk) | 2012-10-02 | 2019-04-25 | Женеро Са | Фармацевтична композиція для лікування блокади ремієлінізації при захворюваннях, які пов'язані з експресією білка оболонки herv-w |
| AR094277A1 (es) | 2012-12-21 | 2015-07-22 | Biogen Idec Inc | Derivados de fumarato sustituidos con deuterio |
| US8669281B1 (en) | 2013-03-14 | 2014-03-11 | Alkermes Pharma Ireland Limited | Prodrugs of fumarates and their use in treating various diseases |
| MX386935B (es) | 2013-03-14 | 2025-03-04 | Alkermes Pharma Ireland Ltd | Profármacos de fumaratos y su uso en el tratamiento de diferentes enfermedades. |
| US10179118B2 (en) | 2013-03-24 | 2019-01-15 | Arbor Pharmaceuticals, Llc | Pharmaceutical compositions of dimethyl fumarate |
| US9549909B2 (en) | 2013-05-03 | 2017-01-24 | The Katholieke Universiteit Leuven | Method for the treatment of dravet syndrome |
| WO2014197860A1 (en) | 2013-06-07 | 2014-12-11 | Xenoport, Inc. | Method of making monomethyl fumarate |
| US9421182B2 (en) | 2013-06-21 | 2016-08-23 | Xenoport, Inc. | Cocrystals of dimethyl fumarate |
| JP2016534133A (ja) | 2013-09-06 | 2016-11-04 | ゼノポート，インコーポレイティド | （ｎ，ｎ−ジエチルカルバモイル）メチル メチル（２ｅ）ブト−２−エン−１，４−ジオエートの結晶形態、その合成方法及び使用 |
| CN103768045B (zh) * | 2013-10-30 | 2015-10-07 | 苏州大学附属第一医院 | 富马酸二甲酯在制备治疗蛛网膜下腔出血后早期脑损伤药物的应用 |
| JP6337135B2 (ja) | 2014-02-24 | 2018-06-06 | アルカーメス ファーマ アイルランド リミテッド | フマル酸エステルのスルホンアミドプロドラッグ及びスルフィンアミドプロドラッグ並びに種々の疾患の治療におけるその使用 |
| US10098863B2 (en) | 2014-02-28 | 2018-10-16 | Banner Life Sciences Llc | Fumarate esters |
| US9326947B1 (en) | 2014-02-28 | 2016-05-03 | Banner Life Sciences Llc | Controlled release fumarate esters |
| US9636318B2 (en) | 2015-08-31 | 2017-05-02 | Banner Life Sciences Llc | Fumarate ester dosage forms |
| CA2939990C (en) | 2014-02-28 | 2018-07-10 | Banner Life Sciences Llc | Controlled release enteric soft capsules of fumarate esters |
| US9999672B2 (en) | 2014-03-24 | 2018-06-19 | Xenoport, Inc. | Pharmaceutical compositions of fumaric acid esters |
| MA40985A (fr) | 2014-11-17 | 2017-09-26 | Biogen Ma Inc | Méthodes de traitement de la sclérose en plaques |
| MA41785A (fr) * | 2015-03-20 | 2018-01-23 | Biogen Ma Inc | Procédés et compositions pour l'administration intraveineuse de fumarates pour le traitement de maladies neurologiques |
| US10689324B2 (en) | 2015-12-22 | 2020-06-23 | Zogenix International Limited | Metabolism resistant fenfluramine analogs and methods of using the same |
| DK3800177T3 (da) | 2015-12-22 | 2025-03-31 | Zogenix International Ltd | Fenfluramin-sammensætninger og fremgangsmåder til fremstilling af samme |
| RU2021106383A (ru) | 2016-08-24 | 2021-04-05 | Зодженикс Интернэшнл Лимитед | Состав для ингибирования образования агонистов 5-ht2b и способы его применения |
| US12097292B2 (en) | 2016-08-28 | 2024-09-24 | Mapi Pharma Ltd. | Process for preparing microparticles containing glatiramer acetate |
| AU2017319728B2 (en) | 2016-08-31 | 2024-09-05 | Mapi Pharma Ltd | Depot systems comprising glatiramer acetate |
| IL316573A (en) | 2017-03-26 | 2024-12-01 | Mapi Pharma Ltd | Storage systems containing glatiramer acetate for the treatment of multiple sclerosis |
| KR102904262B1 (ko) | 2018-01-11 | 2025-12-24 | 엠 이티 피 파마 아게 | 탈수초성 질환의 치료 |
| WO2020105005A1 (en) | 2018-11-19 | 2020-05-28 | Zogenix International Limited | Methods of treating rett syndrome using fenfluramine |
| WO2021142062A1 (en) | 2020-01-10 | 2021-07-15 | Banner Life Sciences Llc | Fumarate ester dosage forms with enhanced gastrointestinal tolerability |
| US11612574B2 (en) | 2020-07-17 | 2023-03-28 | Zogenix International Limited | Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |
| WO2023034115A1 (en) * | 2021-09-01 | 2023-03-09 | Zogenix International Limited | Fenfluramine for treatment of demyelinating diseases and conditions |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3127432A1 (de) * | 1981-07-11 | 1983-02-03 | Bayer Ag, 5090 Leverkusen | Verfahren zur herstellung von fumarsaeuremonoester |
| US5149695A (en) * | 1985-01-15 | 1992-09-22 | Speiser Peter P | Fumaric acid derivatives, process for the production thereof and pharmaceutical compositions containing same |
| CH664150A5 (de) * | 1985-01-15 | 1988-02-15 | Peter Paul Prof Dr Speiser | Fumarsaeureprodrug, verfahren zu seiner herstellung und dieses enthaltende darreichungsformen. |
| JPS61194020A (ja) * | 1985-02-22 | 1986-08-28 | Dai Ichi Seiyaku Co Ltd | 網膜症治療剤 |
| US5214196A (en) * | 1987-09-04 | 1993-05-25 | Dexter Chemical Corporation | Diethyl ester of di-glycyl fumaramide |
| US5242905A (en) * | 1987-09-04 | 1993-09-07 | Dexter Chemical Corporation | Pharmaceutical compositions for the treatment of psoriasis |
| US4959389A (en) * | 1987-10-19 | 1990-09-25 | Speiser Peter P | Pharmaceutical preparation for the treatment of psoriatic arthritis |
| US5424332A (en) * | 1987-10-19 | 1995-06-13 | Speiser; Peter P. | Pharmaceutical composition and process for the production thereof |
| US5484610A (en) * | 1991-01-02 | 1996-01-16 | Macromed, Inc. | pH and temperature sensitive terpolymers for oral drug delivery |
| AU1271592A (en) * | 1991-01-18 | 1992-08-27 | Dexter Chemical Corporation | Malic acid derivatives and compositions for the treatment of psoriasis |
| IT1251166B (it) * | 1991-08-09 | 1995-05-04 | Chiesi Farma Spa | Derivati di geneserina,loro preparazione e composizioni farmaceutiche che li contengono |
| FR2694693B1 (fr) * | 1992-07-28 | 1994-10-28 | Abrax Bio Labs Sa | Composition pharmaceutique à base de flavopéréirine et son utilisation dans un traitement contre le virus VIH. |
| CA2125763C (en) * | 1993-07-02 | 2007-08-28 | Maurice Kent Gately | P40 homodimer of interleukin-12 |
| US5407772A (en) * | 1993-11-30 | 1995-04-18 | Xerox Corporation | Unsaturated polyesters |
| US5972363A (en) * | 1997-04-11 | 1999-10-26 | Rohm And Haas Company | Use of an encapsulated bioactive composition |
| DE19721099C2 (de) | 1997-05-20 | 1999-12-02 | Fumapharm Ag Muri | Verwendung von Fumarsäurederivaten |
| US20050245612A1 (en) * | 2004-05-03 | 2005-11-03 | Blass John P | Pharmaceutical compositions for metabolic insufficiencies |
| US6537969B1 (en) * | 1997-10-24 | 2003-03-25 | John P. Blass | Nutritional supplement for cerebral metabolic insufficiencies |
| DE19814358C2 (de) * | 1998-03-31 | 2002-01-17 | Fumapharm Ag Muri | Verwendung von Alkylhydrogenfumaraten zur Behandlung von Psoriasis, psoriatischer Arthritis, Neurodermitis und Enteritis regionalis Crohn |
| DE19839566C2 (de) * | 1998-08-31 | 2002-01-17 | Fumapharm Ag Muri | Verwendung von Fumarsäurederivaten in der Transplantationsmedizin |
| DE19848260C2 (de) * | 1998-10-20 | 2002-01-17 | Fumapharm Ag Muri | Fumarsäure-Mikrotabletten |
| DE19853487A1 (de) * | 1998-11-19 | 2000-05-25 | Fumapharm Ag Muri | Verwendung von Dialkylfumaraten |
| US6537584B1 (en) * | 1999-11-12 | 2003-03-25 | Macromed, Inc. | Polymer blends that swell in an acidic environment and deswell in a basic environment |
| DE10000577A1 (de) * | 2000-01-10 | 2001-07-26 | Fumapharm Ag Muri | Verwendung von Fumarsäurederivaten zur Behandlung mitochondrialer Krankheiten |
| AU3685401A (en) * | 2000-02-11 | 2001-08-20 | Philadelphia Health | Differentiation of bone marrow cells into neuronal cells and uses therefor |
| AU2001271824A1 (en) * | 2000-07-05 | 2002-01-14 | Johns Hopkins School Of Medicine | Prevention and treatment of neurodegenerative diseases by glutathione and phase ii detoxification enzymes |
| DE10101307A1 (de) * | 2001-01-12 | 2002-08-01 | Fumapharm Ag Muri | Fumarsäurederivate als NF-kappaB-Inhibitor |
| CA2776023A1 (en) * | 2001-01-12 | 2002-07-18 | Fumapharm Ag | Fumaric acid amides |
| JP2004518712A (ja) * | 2001-02-14 | 2004-06-24 | ラート・マティアス | 細胞の生体エネルギー代謝に関与する生化学的化合物の組成物及びそれの使用法 |
| US20030104997A1 (en) * | 2001-09-05 | 2003-06-05 | Black Ira B. | Multi-lineage directed induction of bone marrow stromal cell differentiation |
| DE10217314A1 (de) * | 2002-04-18 | 2003-11-13 | Fumapharm Ag Muri | Carbocyclische und Oxacarboncyclische Fumarsäure-Oligomere |
| US6830759B2 (en) * | 2002-06-28 | 2004-12-14 | Ajinomoto Co., Inc. | Antidiabetic preparation for oral administration |
| DK1663197T3 (da) * | 2003-09-09 | 2008-01-07 | Fumapharm Ag | Anvendelse af fumarsyrederivater til behandling af hjerteinsuffiens og astma |
| AU2005231145B8 (en) * | 2004-03-31 | 2010-11-11 | Bpsi Holdings, Inc. | Enteric coatings for orally ingestible substrates |
| SI1799196T1 (sl) * | 2004-10-08 | 2016-10-28 | Forward Pharma A/S | Farmacevtski sestavki z nadzorovanim sproščanjem, obsegajoči ester fumarne kisline |
| US7638119B2 (en) * | 2004-12-02 | 2009-12-29 | Wisconsin Alumni Research Foundation | Method of diminishing the symptoms of neurodegenerative disease |
| EP1674082A1 (de) * | 2004-12-22 | 2006-06-28 | Zentaris GmbH | Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel |
| JP2008530216A (ja) * | 2005-02-16 | 2008-08-07 | シェーリング コーポレイション | Ｃｘｃｒ３アンタゴニスト活性を有する、複素環で置換された新規のピリジンまたはフェニル化合物 |
| DE102005022845A1 (de) * | 2005-05-18 | 2006-11-23 | Fumapharm Ag | Thiobernsteinsäurederivate und deren Verwendung |
| US20080227847A1 (en) * | 2005-07-07 | 2008-09-18 | Aditech Pharma Ab | Novel Salts of Fumaric Acid Monoalkylesters and Their Pharmaceutical Use |
| EP1940382A2 (en) * | 2005-10-07 | 2008-07-09 | Aditech Pharma AB | Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders |
| US20080089861A1 (en) * | 2006-07-10 | 2008-04-17 | Went Gregory T | Combination therapy for treatment of demyelinating conditions |
| EP2653873B8 (en) * | 2007-02-08 | 2022-08-24 | Biogen MA Inc. | Compositions and uses for treating Multiple Sclerosis |
| HUE032251T2 (hu) | 2007-02-08 | 2017-09-28 | Biogen Ma Inc | Neuroprotekció a demyelinizációs betegségekben |
| US20080274182A1 (en) * | 2007-05-03 | 2008-11-06 | Regina Helena Alida Boekema | Tablet coatings made from modified carboxymethylcellulose materials |
| MX2011001341A (es) * | 2008-08-19 | 2011-03-29 | Xenoport Inc | Prodrogas de metil hidrogeno fumarato, sus composiciones farmaceuticas, y metodos de uso. |
| EP2564839B1 (en) * | 2009-01-09 | 2016-05-11 | Forward Pharma A/S | Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix |
| EP3318249A1 (en) * | 2009-04-29 | 2018-05-09 | Biogen MA Inc. | Dimethyl fumarate dosage regimens for the treatment of multiple sclerosis |
| DK2533634T3 (en) * | 2010-02-12 | 2016-01-25 | Biogen Ma Inc | NEURO PROTECTIVE demyelinating diseases |
| CA2862885C (en) * | 2012-02-07 | 2020-06-02 | Biogen Ma Inc. | Pharmaceutical compositions containing dimethyl fumarate |
-
2008
- 2008-02-07 HU HUE08737369A patent/HUE032251T2/hu unknown
- 2008-02-07 DK DK08737369.2T patent/DK2139467T3/da active
- 2008-02-07 EP EP08737369.2A patent/EP2139467B1/en not_active Revoked
- 2008-02-07 WO PCT/IB2008/000779 patent/WO2008096271A2/en not_active Ceased
- 2008-02-07 ES ES08737369.2T patent/ES2599227T3/es active Active
- 2008-02-07 LT LTEP08737369.2T patent/LT2139467T/lt unknown
- 2008-02-07 PT PT87373692T patent/PT2139467T/pt unknown
- 2008-02-07 SI SI200831679A patent/SI2139467T1/sl unknown
- 2008-02-07 PL PL08737369T patent/PL2139467T3/pl unknown
- 2008-02-07 US US12/525,805 patent/US20100130607A1/en not_active Abandoned
- 2008-02-07 EP EP16188566.0A patent/EP3135282A1/en not_active Withdrawn
- 2008-02-07 RS RS20160808A patent/RS55215B1/sr unknown
- 2008-02-07 HR HRP20161233TT patent/HRP20161233T1/hr unknown
-
2013
- 2013-03-14 US US13/826,354 patent/US20130302410A1/en not_active Abandoned
-
2014
- 2014-04-29 US US14/264,653 patent/US20140323570A1/en not_active Abandoned
-
2018
- 2018-05-25 US US15/989,683 patent/US20180271821A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3135282A1 (en) | 2017-03-01 |
| EP2139467A2 (en) | 2010-01-06 |
| US20100130607A1 (en) | 2010-05-27 |
| DK2139467T3 (da) | 2017-01-02 |
| US20180271821A1 (en) | 2018-09-27 |
| PL2139467T3 (pl) | 2017-08-31 |
| US20140323570A1 (en) | 2014-10-30 |
| EP2139467B1 (en) | 2016-09-21 |
| RS55215B1 (sr) | 2017-02-28 |
| PT2139467T (pt) | 2016-12-16 |
| US20130302410A1 (en) | 2013-11-14 |
| HK1140413A1 (zh) | 2010-10-15 |
| WO2008096271A3 (en) | 2008-11-27 |
| SI2139467T1 (sl) | 2017-01-31 |
| WO2008096271A2 (en) | 2008-08-14 |
| ES2599227T3 (es) | 2017-01-31 |
| HRP20161233T1 (hr) | 2016-12-02 |
| LT2139467T (lt) | 2016-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2139467B1 (en) | Neuroprotection in demyelinating diseases | |
| Pakkenberg et al. | Clozapine in the treatment of tremor | |
| US20170319570A1 (en) | Treatment of Multiple Sclerosis With Combination of Laquinimod and Dimethyl Fumarate | |
| US20140163100A1 (en) | Methods of Treating Multiple Sclerosis and Preserving and/or Increasing Myelin Content | |
| DE69827853T2 (de) | Verwendung von Ibudilast zur Herstellung eines Arzneimittels zur Behandlung von multipler Sklerose | |
| Gold et al. | Neuroprotection in Demyelinating Diseases | |
| Gold et al. | Neuroprotection in Demyelinating Diseases | |
| RS54551B1 (sr) | Neuroprotekcija kod demijelinizujućih bolesti | |
| Gold | Neuroprotection in demyelinating diseases | |
| EP3094616B1 (en) | The use of glyceryl tribenzoate containing composition in neurodegenerative disorders | |
| EP3761982B1 (en) | Use of nalfurafine for the treatment of demyelinating diseases | |
| JP2023515429A (ja) | 多発性硬化症患者の亜集団の処置のためのマシチニブ | |
| EP2490685B1 (en) | Causal therapy of diseases or conditions associated with cns or pns demyelination | |
| CN117915959A (zh) | 使用经遗传修饰的病毒载体治疗年龄相关认知衰退 | |
| HK1140413B (en) | Neuroprotection in demyelinating diseases | |
| US20220233503A1 (en) | Methods of treating sepsis with synaptic vesicle 2a and/or 2b binding chemical entities | |
| US20070238711A1 (en) | Combination Therapy with Glatiramer Acetate and Minocycline for the Treatment of Multiple Sclerosis | |
| IL324171A (en) | Mivelsiran compositions and methods of use thereof | |
| WO2004078145A2 (en) | Combination therapy with glatiramer acetate and simvastatin for the treatment of multiple sclerosis |